Kyverna Therapeutics (KYTX) Research & Development (2023 - 2026)

Kyverna Therapeutics' Research & Development history runs 4 years deep, the most recent figure standing at $30.1 million for Q1 2026.

• Quarterly Research & Development fell 19.66% year-over-year to $30.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $126.4 million (down 0.84% YoY) and the FY2025 annual result came in at $133.7 million, up 18.89% from the prior year.
• Research & Development was $30.1 million for Q1 2026 at Kyverna Therapeutics, roughly flat from $30.0 million in the prior quarter.
• Across five years, Research & Development topped out at $37.4 million in Q1 2025 and bottomed at $8.7 million in Q1 2023.
• A 4-year average of $25.1 million and a median of $29.2 million in 2024 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2024 — Research & Development surged 162.58% — and 2026, when it retreated 19.66%.
• Kyverna Therapeutics' Research & Development stood at $17.2 million in 2023, then jumped by 95.09% to $33.5 million in 2024, then decreased by 10.36% to $30.0 million in 2025, then rose by 0.2% to $30.1 million in 2026.
• Business Quant data shows KYTX's Research & Development at $30.1 million in Q1 2026, $30.0 million in Q4 2025, and $30.5 million in Q3 2025.